Eli Lilly & Co. (LLY) Reports In-Line Q2 EPS; Offers Longer-Term Guidance Update
Get Alerts LLY Hot Sheet
Price: $745.69 +1.96%
EPS Growth %: +51.9%
Financial Fact:
Cost of sales: 1.4B
Today's EPS Names:
SFST, VLTO, CLIR, More
EPS Growth %: +51.9%
Financial Fact:
Cost of sales: 1.4B
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Eli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $0.86, in-line with the analyst estimate of $0.86. Revenue for the quarter came in at $5.4 billion versus the consensus estimate of $5.15 billion.
- The company provides updated financial expectations through the remainder of the decade, including at least 5 percent average annual revenue growth driven by volume, along with an increase in gross margin as a percent of revenue, both on a constant currency basis. The company also plans to return to annual dividend increases for shareholders and reaffirmed its commitment to achieve an OPEX-to-revenue ratio of 50 percent or less in 2018.
- Significant pipeline progress continued with regulatory approval of Taltz in Japan, priority review granted for olaratumab in the U.S., a positive FDA Advisory Committee vote on Jardiance and an encouraging Phase 2 data read-out for abemaciclib.
Eli Lilly & Co. reaffirmed FY2016 guidance.
For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Texas Instruments (TXN) jumps as on earnings, revenue beat in fiscal Q1
- Veralto Corporation (VLTO) Tops Q1 EPS by 6c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
Earnings, AdComSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!